Chart of Day: Viking Therapeutics (VKTX) Explodes Again – 3/28

On March 21, we noted, “When we first mentioned Viking Therapeutics (VKTX) with the Chart of Day, it traded at around $35 a share on February 20. By March 5, it was above $92 a share. Today, after slipping to $66.72 on competitor trial news, VKTX is starting to push higher again. Last trading at $66.72, we’d like to see it challenge $92 again shortly.”

Today, VKTX is up to $85 on a volume spike to 10.47 million shares, as compared to its daily average of 6.18 million.


All thanks to its latest promising new weight loss pill data. Based on the latest results, Viking plans to start Phase 2 trials of its once-a-day weight loss pill later this year. This is the oral version of the company’s weight loss injection, which is also showing encouraging results in mid-stage trials.

As noted by CNBC, “The phase one trial for the pill followed more than 40 patients with obesity for around a month. Those people took different dose sizes of the drug or received a placebo. Viking said patients who received the pill once a day lost up to 5.3% of their weight on average, or up to 3.3% more than those who took a placebo, at 28 days.”

“Up to 57% of patients who received Viking’s pill lost at least 5% of their body weight. Meanwhile, no people who took the placebo shed that much weight.”

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.